Clinical Pharmacokinetics and Pharmacodynamics of Finasteride

    January 1996 in “Clinical Pharmacokinectics
    Joseph P. Steiner
    Image of study
    TLDR Finasteride helps regrow hair and shrink prostate by reducing DHT, with some sexual side effects.
    This document from 1996 discusses the pharmacokinetics and pharmacodynamics of finasteride, a drug used to treat benign prostatic hyperplasia (BPH) and male pattern baldness. Finasteride inhibits the enzyme 5α-reductase, which is responsible for converting testosterone to dihydrotestosterone (DHT). By inhibiting this enzyme, finasteride reduces the amount of DHT in the body, which can lead to hair regrowth and a reduction in prostate size. The drug is well-tolerated, with loss of libido and sexual potency being the most commonly reported adverse reactions. The document also discusses the different types of 5α-reductase isoenzymes and their roles in male sexual development.
    View this study on →

    Cited in this study